---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-090405"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T17:58:21.104240+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Crinetics R&D Day updates preclinical pipeline: TSHR antagonist, SST3 agonist, NDC platform

## Summary
- CRN12755 (TSHR antagonist) decreased thyroid hormone (T4) in rat model and hyaluronic acid/IL-6 in TED patient orbital fibroblasts.
- CRN10329 (SST3 agonist) reduced cystic index, kidney weight, and injury markers in ADPKD mouse model; SST3 highly expressed in cyst-lining cells.
- CRN09682 (NDC) showed dose-dependent anti-tumor activity in mouse models; free MMAE persisted in tumor >240 hours, cleared from plasma by 24 hours.
- Phase 1/2 BRAVESST2 trial of CRN09682 expects up to 150 participants; Phase 1 dose escalation: 3-6 patients per cohort.

## SEC filing metadata
- accession: 0000950170-25-090405
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017025090405/0000950170-25-090405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017025090405/crnx-20250626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-090405
- JSON: https://secwatch.observer/filing/0000950170-25-090405.json
- Plain text: https://secwatch.observer/filing/0000950170-25-090405.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.